Cooley LLP announced today that it advised Celladon Corporation on its initial public offering. Celladon is a clinical-stage biotechnology company that targets SERCA enzymes to develop novel therapies for diseases with tremendous unmet medical needs. The company now trades on the NSADAQ Global Stock Market under the symbol, “CLDN.”
The Cooley corporate and securities team advising Celladon was led by partner Jason Kent and included associates Kristin VanderPas, Asa Henin, Rebecca Jones, Nathan Figler, Dani Nazemian and Jessica Wade. Critical support for the offering was provided by partner Wendy Goldstein, associate Jennifer Shanley and partner Natasha Leskovsek (healthcare & life sciences regulatory), and associate Megan Arthur (compensation & benefits).
This offering follows Cooley’s record year in 2013 for capital markets in which the firm advised on 60 public offerings, including 23 IPOs, raising more than $8.4 billion. Year-to-date, Cooley has advised on 20 public offerings, including 10 IPOs.
